Previous 10 | Next 10 |
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that neither L...
New data supports the future development of LP-100 in combination with PARP inhibitors for earlier lines of treatment including metastatic prostate cancer and other indications where PARP inhibitors are being utilized. Synergistic potency was observed for LP-100 in combination with multiple P...
Webinar to be hosted on Tuesday, March 21, 2023 at 12:00 p.m. ET, register here , or at the link below. Dr. Zoltan Szallasi will provide a high-level overview of synthetic lethality, why synthetic lethality has become a desired trait for drugs in oncology, and an in-depth look at how Lant...
2023-03-06 09:37:06 ET Lantern Pharma ( NASDAQ: LTRN ) said it has formed a wholly-owned subsidiary called Starlight Therapeutics to focus exclusively on developing therapies for central nervous system (CNS) and brain cancers. Starlight will develop drug candidate ...
Starlight Therapeutics Inc., a Lantern subsidiary, will focus exclusively on the clinical development of therapies for CNS (central nervous system) and brain cancers with limited or no effective therapeutic options. Lantern's AI platform, RADR ® , aided in the identification and acce...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has ex...
Collaborative efforts are aimed at using Lantern’s AI platform to accelerate and sharpen the drug development of TTC-352. The collaboration will utilize Lantern’s AI-based capabilities and RADR ® platform to uncover efficacy-associated biological signatures and biomarke...
Lantern is expanding RADR ® ’s product roadmap to enhance the development of novel and effective Antibody Drug Conjugates (ADCs) for the targeted delivery of potent anti-cancer small molecules to cancer cells. RADR ® ’s AI and ML drug development modules have t...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today an...
Lantern Pharma ( NASDAQ: LTRN ) on Thursday said the U.S. Food and Drug Administration (FDA) had granted an orphan drug designation to its LP-284 candidate for the treatment of mantle cell lymphoma (MCL). MCL is a rare and aggressive form of B-cell non-Hodgkin's lymphoma that is typic...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...